The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical outcomes of chemotherapy rechallenge in patients with metastatic non-small cell lung (NSCLC) who progressed on immunotherapy maintenance after front line platinum doublets and immunotherapy.
 
Kaiwen Wang
Consulting or Advisory Role - BluPrint Oncology
(OPTIONAL) Uncompensated Relationships - Janssen Scientific Affairs
 
Frank V. Fossella
No Relationships to Disclose
 
Marcelo Vailati Negrao
Consulting or Advisory Role - Genentech; Merck; Mirati Therapeutics; Novartis
Research Funding - Alaunos Therapeutics (Inst); AstraZeneca (Inst); Checkmate Pharmaceuticals (Inst); Genentech (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst)
Other Relationship - Apothecom; Ashfield Healthcare; ZIOPHARM Oncology
 
Tina Cascone
Honoraria - Brystol-Myers Squibb; IDEOlogy Health; Mark Foundation for Cancer Research; Medscape; Onclive; Peerview; Roche; Society for Immunotherapy of Cancer
Consulting or Advisory Role - Arrowhead Pharmaceuticals; Bristol Myers Squibb; EMD Serono; Genentech; MedImmune; Merck; Regeneron
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); MedImmune (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Dava Oncology; IASLC; IDEOlogy Health; Parker Institute for Cancer Immunotherapy; Society for Immunotherapy of Cancer
 
Carl Michael Gay
Honoraria - Aptitude Health; OncLive/MJH Life Sciences; Peerview
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; G1 Therapeutics; Jazz Pharmaceuticals; KisoJi Biotechnology; Monte Rosa Therapeutics; Pharmerit
Speakers' Bureau - AstraZeneca; BeiGene
Research Funding - AstraZeneca
Patents, Royalties, Other Intellectual Property - Patent pending related to small cell lung cancer transcriptional subtypes.
Travel, Accommodations, Expenses - Dava Oncology; ESMO
 
Xiuning Le
Consulting or Advisory Role - Abbvie; ArriVent Biopharma; AstraZeneca; Blueprint Medicines; Daiichi Sankyo/Lilly; EMD Serono; Hengrui Therapeutics; Janssen Oncology; Lilly; Novartis; Sensei Biotherapeutics; Spectrum Pharmaceuticals
Research Funding - ArriVent Biopharma (Inst); Boehringer Ingelheim (Inst); Lilly (Inst); Regeneron (Inst); Teligene (Inst)
Travel, Accommodations, Expenses - EMD Serono; Spectrum Pharmaceuticals
 
Natalie I Vokes
Honoraria - Sanofi
Consulting or Advisory Role - Lilly; OncoCyte; Regeneron; Sanofi; Sanofi/Regeneron
Research Funding - Mirati Therapeutics; OncoCyte
Travel, Accommodations, Expenses - Regeneron
 
Celyne Bueno Hume
No Relationships to Disclose
 
Amy Aida Hassan
No Relationships to Disclose
 
Don Lynn Gibbons
Stock and Other Ownership Interests - Exact Sciences; Nektar
Consulting or Advisory Role - 4D Pharma; AstraZeneca; Lilly; Menarini; Onconova Therapeutics; Sanofi
Research Funding - Astellas Pharma; AstraZeneca (Inst); Boehringer Ingelheim (Inst); Janssen; NGM Biopharmaceuticals; Ribon Therapeutics; Takeda
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; BerGenBio; Takeda
 
J. Jack Lee
Honoraria - AstraZeneca; AstraZeneca
 
John Heymach
Consulting or Advisory Role - AstraZeneca; BerGenBio; Boehringer Ingelheim; Bristol-Myers Squibb; DAVA Pharmaceuticals; EMD Serono; Genentech/Roche; GlaxoSmithKline; Hengrui Pharmaceutical; Janssen; Jazz Pharmaceuticals; Jazz Pharmaceuticals; Lilly (Inst); Mirati Therapeutics; Nexus Health Systems; Pneuma Respiratory; Regeneron; Sanofi/Aventis; Spectrum Pharmaceuticals; Takeda
Speakers' Bureau - DAVA Pharmaceuticals; IDEOlogy Health; MJH Life Sciences
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Spectrum Pharmaceuticals; Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Licensing agreement between Spectrum and MD Anderson (including myself) regarding intellectual property for treatment of EGFR and HER2 exon 20 mutations
 
Jianjun Zhang
Honoraria - CancerNet; Geneplus; Geneplus; Hengrui Medicine; innovent biologics; Innovent Biologics; Innovent Biologics; Origimed; Roche; Sino-USA Biomedical Platform; Suzhou Medical Association; Varian Medical Systems; Zhejiang Cancer Hospital; Zhejiang Cancer Hospital; Zhejiang Cancer Hospital
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; Capital Medical University; Geneplus; Hunan Cancer Hospital; Johnson & Johnson/Janssen; Novartis
Research Funding - Merck; Novartis
Travel, Accommodations, Expenses - innovent biologics; Zhejiang Cancer Hospital